Rosuvastatin Effect on Atherosclerotic Plaque Metabolism (ROPPET-NAF)

October 27, 2022 updated by: Manuel Oliveira Santos, University of Coimbra

Rosuvastatin Effect on Atherosclerotic Plaque Metabolism - a Subclinical Atherosclerosis Imaging Study With 18F-NaF PET-CT

Atherosclerotic plaque uptake of 18F-sodium fluoride (NaF) in positron emission tomography with computed tomography (PET-CT) was recently shown to correlate with clinical instability in patients with CV disease. We hypothesize that rosuvastatin reduces 18F-NaF plaque uptake.

Our group will scan coronary, aortic and carotid arteries of high-risk CV subjects with 18F- NaF-PET-CT. Individuals with 18F-NaF-positive plaques will be treated with rosuvastatin for six months, followed by 18F-NaF-PET-CT re-evaluation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background:

Cardiovascular diseases (CVD) are the main cause of mortality in developed countries; its prevention is challenging. Advances in molecular imaging of the atherosclerotic plaque enhanced the study of its pathophysiology, including the positron emission tomography with computed tomography (PET-CT) scan. The marker 18F-sodium fluoride (NaF) has been studied in peripheral arteries plaque imaging as an in vivo marker of on-going calcification. The 18F ions deposit in the bone by exchange of hydroxyl group on the surface of the hydroxyapatite matrix to form fluoroapatite, so this tracer detects areas of active calcification and osteogenic remodeling. Coronary imaging with 18F-NaF labelled PET-CT was recently described and proposed to be able to discriminate between active and inactive coronary calcification, possibly identifying high-risk patients.

Statin therapy is approved for primary and secondary CVD prevention due to both its cholesterol-lowering effect and positive pleiotropic properties in the plaque. In particular, rosuvastatin diminishes mortality and vascular events when used in primary and secondary prevention. High doses of rosuvastatin resulted in atherosclerosis regression as assessed with coronary intravascular ultrasound, carotid intima-media thickness (CIMT) and lipid content reduction of the atherosclerotic plaque (near-infrared spectroscopy analysis).

We do not know the effects of statins in the 18F-NaF uptake.

Design:

Investigator's initiative prospective study of 18F-NaF-PET-CT coronary, aortic and carotid plaques imaging in primary prevention subjects, with a before and after experiment with rosuvastatin treatment and long-term follow-up. The protocol was approved by the Ethics Committee of Faculty of Medicine of the University of Coimbra and written according to Good Clinical Practice and the Declaration of Helsinki.

Taks:

  1. Screening - visit 0:

    Patients followed at the Arterial Hypertension clinic of Centro Hospitalar e Universitário de Coimbra will be screened and selected if they meet all of the inclusion criteria.

  2. Baseline assessment:

    Clinical questionnaire and standard physical examination. CV risk will be estimated according to SCORE equations and the American Heart Association atherosclerotic cardiovascular disease calculator. Patients' medical history and CV risk factors will be recorded, as well as physical examination findings, including age, race, gender, smoking status (current, past, quantification with pack-years), diabetes mellitus (type 1, 2, pre- diabetes), family history of premature coronary heart disease (first degree: men < 55 and women < 65 years old), relevant past medical history, blood pressure, heart rate, weight and height. Levels of total cholesterol, high and low-density lipoprotein cholesterol (HDL and LDL), triglycerides, creatinine, creatine kinase, alanine amino-transferase, aspartate amino- transferase, gamma-glutamyl transpeptidase, alkaline phosphatase, glycated hemoglobin, fasting glucose, high-sensitivity C-reactive protein and haemoglobin will be determined.

  3. Baseline 18F-NaF labelled PET-CT - visit 1:

    Patients will undergo whole body 18F-NaF-PET-CT for identification of coronary, carotid, thoracic and abdominal aorta arteries plaques and quantification of 18F-NaF uptake (tissue-to-background ratio (TBR)). Scans will be reviewed and analysed by experienced observers blinded to the clinical diagnosis. Subjects without 18F-NaF-positive plaques will be excluded from the pharmacological intervention study.

  4. Rosuvastatin treatment:

    At visit 1, patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg).

  5. Second 18F-NaF labelled PET-CT - visit 3:

Subjects will undergo a second PET-CT scan six months after statin treatment to assess changes in 18F-NaF plaque uptake. Medication compliance will be monitored, as well as adverse events reporting.

Statistical analysis:

18F-NaF uptake after rosuvastatin treatment will be compared to baseline values with paired samples T student test or Wilcoxon text according to the normality of the distribution. Sample size was estimated according to the preliminary results of 25 subjects (pilot study) and the primary endpoint of reducing maximum 18F-NaF uptake as assessed by TBR. Individuals with no significant 18F-NaF uptake were excluded from this analysis (n=4): mean TBR 2.16 and SD 0.40. At 90% power and a significance level of 0.05, assuming a correlation of 0.8 and 10% difference in TBR, the calculated sample size is 32. As only 21 out of 25 subjects in the pilot study displayed criteria for the pharmacological study, it is necessary to perform 44 baseline studies, followed by 36 subjects re-evaluation (drop-out margin of 4 subjects), totaling 80 PET-CT scans.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Portugal
      • Coimbra, Portugal, 3000-075
        • Centro Hospitalar e Universitário de Coimbra

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Older than 40 years;
  2. Written informed consent;

  3. Considered to be at high or very high CV risk according to the European Society of Cardiology guidelines, fulfilling any of the following criteria:

    • predicted fatal CV event at 10 years ≥5% (SCORE tables for low-risk countries);
    • chronic kidney disease with glomerular filtration rate (GFR) under 60 mL/min (Modification of Diet in Renal Disease equation - MDRD);
    • diabetes mellitus (type 1 or 2);
    • markedly elevated single risk factors.

Exclusion Criteria:

  • Previous CV events;
  • GFR under 30 mL/min;
  • Known hepatic dysfunction or alanine amino-transferase level more than twice the upper limit of the normal (ULN) range;
  • Creatine kinase level more than three times the ULN;
  • Known myopathy;
  • Statin hypersensivity;
  • Hormone replacement therapy;
  • Malignant neoplasms in the past five years (excluding basal-cell skin carcinoma);
  • Uncontrolled hypothyroidism;
  • Chronic inflammatory disease (such as rheumatoid arthritis, inflammatory bowel disease);
  • Pregnancy or women in child bearing age without contraceptive;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients with positive 18F-NaF plaques
Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
Drug: Rosuvastatin Oral Tablet
Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
No Intervention: Patients without 18F-NaF-positive plaques
Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Variation in 18F-NaF uptake in coronary, aortic and carotid plaques (tissue to background ratio - TBR)
Time Frame: 6 months
  • Whole body 18F-NaF-PET-CT for identification of coronary, carotid, thoracic and abdominal aorta arteries plaques:
  • administration of 125 MBq 18F-NaF intravenously, followed by an attenuation correction CT scan and PET imaging after 60 min. Coronary images will be reconstructed according with the usual protocol of PET-CT. Two-dimensional regions of interest will be drawn around all major epicardial coronary vessels and around the major vessels on three millimetres axial slices.
  • Quantification of 18F-NaF uptake at baseline and after optimal treatment including statins:
  • ratio of the maximum standard uptake value (SUV) in the region of interest (the decay corrected tissue concentration of the tracer divided by the injected dose per bodyweight) and blood pool activity in the superior vena cava: tissue-to-background ratio (TBR).
  • Primary outcome: variation in maximum TBR at any vascular territory (coronary, carotid or aortic)
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Variation in 18F-NaF uptake in coronary, aortic and carotid plaques (corrected uptake per lesion - CUL)
Time Frame: 6 months
  • Quantification of 18F-NaF uptake at baseline and after optimal medical treatment
  • difference between the maximum SUV in the region of interest and blood pool activity in the superior vena cava: corrected uptake per lesion - CUL.
  • Primary outcome: variation in maximum CUL at any vascular territory (coronary, carotid or aorta)
6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety outcome
Time Frame: 6 months
Adverse events monitoring related with medical treatment namely statins: myalgia, myopathy (CK), hepatotoxicity (ALT), gastrointestinal symptoms.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Coimbra

Collaborators

AstraZeneca

Investigators

  • Study Director: Miguel Castelo-Branco, PhD, Coimbra's University - Faculty of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 27, 2020

Primary Completion (Actual)

June 20, 2022

Study Completion (Actual)

October 27, 2022

Study Registration Dates

First Submitted

July 25, 2017

First Submitted That Met QC Criteria

July 25, 2017

First Posted (Actual)

July 28, 2017

Study Record Updates

Last Update Posted (Actual)

October 28, 2022

Last Update Submitted That Met QC Criteria

October 27, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ICNAS-2016-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Rosuvastatin Oral Tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe